Conavi Medical Corp Stock Price, News & Analysis

Conavi Medical reported Q2 2025 fiscal results and key operational updates. The company secured a $20M financing round led by U.S. institutional investors to support the development and launch of its next-generation Novasight Hybrid System, planned for H1 2026. The FDA 510(k) submission remains on schedule for Q3 2025. Q2 2025 financial results showed revenue of $58,000, down from $589,000 year-over-year, with operating expenses of $5.6M and a net loss of $3.1M. Recent developments include new U.S. intracoronary imaging guidelines supporting Novasight's technology, design freeze completion of the next-gen system, and uplisting to OTCQB. The company's cash position was $1M as of March 31, 2025, not including the subsequent $20M financing.

Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) announced that its Novasight Hybrid™ System has been awarded "Product Innovation of the Year" at the 2025 Minnesota Manufacturing Awards. The Novasight system is pioneering as the first commercial device to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies for simultaneous, co-registered imaging of coronary arteries. This innovative technology provides interventional cardiologists with comprehensive insights during complex coronary procedures.

The award, presented by the Minneapolis/St. Paul Business Journal, recognizes Conavi's collaboration with Minnesota-based Minnetronix Medical. The company and its technology will be featured in a special publication on July 18, 2025.

Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), a commercial stage medical device company specializing in imaging technologies for minimally invasive cardiovascular procedures, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference.

CEO Thomas Looby will present on Tuesday, May 6, 2025, at 3:00 p.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be accessible via webcast, with replay available for 90 days on Conavi's Investor Relations website.

The conference facilitates connections between U.S., Canadian, and international investors interested in Canadian healthcare sector developments, offering corporate updates through presentations and private meetings with leading public and private companies.

Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) held its annual general meeting on March 31, 2025, with 30,075,712 common shares voted, representing 67.97% of outstanding shares. Key outcomes include:

• Election of seven directors: Thomas Looby, Aaron Davidson, Craig Podolsky, Robert D. Mitchell, Susan Allen, Cathy Steiner, and Anthony J. Giovinazzo
• Appointment of PricewaterhouseCoopers LLP as auditors
• Approval of amendments to the Omnibus Equity Incentive Plan, removing restrictions on insider participation

The plan maintains its maximum share issuance limit of 8,850,017 common shares (20% of outstanding shares as of October 11, 2024). The amendments await TSXV approval, and options granted under the modified plan cannot be exercised until approval is received.

Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) has received approval for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading scheduled to begin on March 6, 2025. The company will maintain its ticker symbol CNVIF, and no shareholder action is required.

The OTCQB listing, which complements Conavi's TSX Venture Exchange presence, is expected to enhance visibility and access to U.S. investors. The move coincides with the company's preparations for the commercial launch of their next-generation Novasight system.

The OTCQB Venture Market, operated by OTC Markets Group, is recognized by the SEC as an established public market for securities registration purposes. Listed companies must maintain current reporting status and undergo annual verification processes.

Conavi Medical (OTC: CNVIF) received strong validation from new U.S. intracoronary imaging guidelines issued by the American College of Cardiology and American Heart Association. The Class 1A guidelines, representing the highest level of evidence, emphasize the essential roles of both IVUS and OCT imaging in coronary procedures.

The guidelines specifically highlight how these imaging technologies are important for evaluating lesion preparation, stent sizing, reducing geographical errors, confirming stent expansion, identifying complications, and determining stent failure causes. Clinical data shows intracoronary imaging leads to a 46% reduction in cardiac death compared to angiography alone.

Conavi's Novasight system, as the only hybrid IVUS-OCT device in the market, uniquely positions the company by offering both imaging modalities in a single platform. This combination helps streamline procedures, limit contrast usage, and support more informed clinical decisions for complex coronary artery disease patients.

Conavi Medical (TSXV: CNVI) reported its fiscal Q1 2025 results, marking its first quarter as a public company. The company raised $10.6 million CAD through a concurrent private placement and completed a reverse takeover of Titan Medical Inc.

Revenue reached $8.6 million, up from $0.7 million year-over-year, primarily due to an $8.4 million milestone payment from East Ocean Medical following Chinese regulatory approval. Operating expenses increased to $6.8 million from $5.1 million, with R&D expenses at $4.7 million. The company reported a net loss of $7.6 million ($0.19 per share).

Key developments include:

• Completion of next-generation Novasight design freeze
• Initiation of usability testing and system validation
• FDA submission planned for Q3 2025
• Cash position of $5.1 million as of December 31, 2024